Rational identification of a novel peptide for targeting nanocarriers to 9L glioma.

Published

Journal Article

Traditional therapies for high grade gliomas are limited in part by collateral damage to normal tissues. Selective delivery of therapies to tumors is, therefore, needed. Here, we report that liposomal nanocarriers coated with a novel oligopeptide enhance uptake by 9L gliosarcoma. A targeting nine amino acid peptide sequence (RSI) was identified by differential panning of random peptide phage display libraries on 9L cells and rat blood cells and plasma. Peptides were coupled to the surface of liposomal nanocarriers which were subsequently loaded with doxorubicin. The ability of RSI coated liposomes to facilitate drug uptake and cytotoxicity was compared with conventional liposomal nanocarriers and controls. In addition, plasma clearance profiles of the RSI peptide coupled liposomal nanocarriers were evaluated in adult immuno-competent rats. RSI peptide-coupled liposomal nanocarriers enhanced drug uptake by 9L cells by 500% compared with conventional liposomal nanocarriers, and significantly increased cytotoxicity. The plasma half-lives confirmed that the presence of the RSI peptide on the liposomal nanocarriers did not compromise circulation time in the blood in comparison with Stealth liposomal nanocarriers. These data suggest that phage-identified oligopeptides could lead to the development of new tumor selective nanocarriers.

Full Text

Duke Authors

Cited Authors

  • Agarwal, A; Jaye, DL; Giegerman, CM; Bellamkonda, RV

Published Date

  • December 2008

Published In

Volume / Issue

  • 87 / 3

Start / End Page

  • 728 - 738

PubMed ID

  • 18200546

Pubmed Central ID

  • 18200546

Electronic International Standard Serial Number (EISSN)

  • 1552-4965

International Standard Serial Number (ISSN)

  • 1549-3296

Digital Object Identifier (DOI)

  • 10.1002/jbm.a.31762

Language

  • eng